File Not Found The page you requested does not exist on our servers or has been moved. If you have reached this page from a bookmark or favorite, please update your links. Return to the homepage

IMPORTANT SAFETY INFORMATION

Penlac®, part of a comprehensive management program, includes regular removal of the unattached, infected nail by a health care professional, especially for patients with diabetes. Clinical data regarding use of systemic antifungals and Penlac® is not available to support concomitant use. Penlac® is well-tolerated: treatment-related side effects were periungual erythema (5%) and nail disorders (2%).

Patients with insulin-dependent diabetes or those with diabetic neuropathy were not included in pivotal clinical trials with Penlac®.

For more information, please see Full Prescribing Information for Penlac®

Contact Us | Site Map

This site is intended for U.S. residents only.

Dermik Laboratories conducts the U.S. dermatology business of sanofi-aventis U.S. LLC.

©2002-2008 Dermik Laboratories, a business of sanofi-aventis U.S. LLC
Legal Disclaimer and Privacy Policy

US.CIL.07.10.001 Last Update: October 2007

Your privacy
Dermik Laboratories respects your interest in keeping your personal health information private. The information you provide below will be used only for the purpose of sending an email message to the recipient and will not be saved. For more information, see our Privacy Policy.

Your name:

Your email address:

Recipient's email address:

Processing...

Thank you!
Your email has been sent.